Home › Funds › Ikarian Capital, LLC › PRQR
Ikarian Capital, LLC position in PRQR
PROQR THRAPEUTICS N V · Health Care
Ikarian Capital, LLC reported holding 3,425,930 shares of PRQR (PROQR THRAPEUTICS N V) in its Q2 2026 13F filing — a position valued at US$6.4M, representing 1.02% of its reported portfolio and ranking #30 among its reported holdings. Ikarian Capital, LLC has disclosed PRQR holdings in 10 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Ikarian Capital, LLC's PRQR position evolved
Ikarian Capital, LLC first disclosed a stake in PRQR in Q3 2023 at 472,625 shares (US$614K). The position peaked in Q2 2026 at 3,425,930 shares, worth US$6.4M. Across 10 filings, Ikarian Capital, LLC increased the stake 4 time(s), trimmed it 0 time(s) and left it unchanged 4 time(s). The most recent filing (Q2 2026) shows 3,425,930 shares valued at US$6.4M — an increase of 1,933,701 shares quarter over quarter.. Notable position changes include a 67% increase in Q4 2025 (shares fell 20% over the following quarter), a 130% increase in Q2 2026 (shares fell 11% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 472.62K | $614.41K | New |
| Q4 2023 | 472.62K | $935.80K | Hold |
| Q1 2024 | 483.58K | $1.10M | Add |
| Q2 2024 | 483.58K | $802.75K | Hold |
| Q3 2024 | 483.58K | $880.12K | Hold |
| Q2 2025 | 868.07K | $1.77M | New |
| Q3 2025 | 892.23K | $1.90M | Add |
| Q4 2025 | 1.49M | $3.01M | Add |
| Q1 2026 | 1.49M | $2.42M | Hold |
| Q2 2026 | 3.43M | $6.37M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About PRQR and 13F data
PRQR (PROQR THRAPEUTICS N V) is a Health Care company. 35 other funds we track also report a position in PRQR — the largest reported positions include Privium Fund Management B.V. (US$10.3M), HEIGHTS CAPITAL MANAGEMENT, INC (US$5.1M), Kynam Capital Management, LP (US$2.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding PRQR
- Privium Fund Management B.V. 5.52M sh · $10.27M · Q2 2026
- HEIGHTS CAPITAL MANAGEMENT, INC 2.76M sh · $5.14M · Q2 2026
- Kynam Capital Management, LP 1.57M sh · $2.91M · Q2 2026
- DAFNA Capital Management LLC 1.53M sh · $2.85M · Q2 2026
- Squadron Capital Management LLC 1.51M sh · $2.81M · Q2 2026
- M28 Capital Management LP 599.79K sh · $1.12M · Q2 2026
- Lynx1 Capital Management LP 521.41K sh · $969.83K · Q2 2026
- Monaco Asset Management SAM 244.49K sh · $454.75K · Q2 2026
More on Ikarian Capital, LLC
FAQ
How long has Ikarian Capital, LLC held PRQR?
Ikarian Capital, LLC has disclosed PRQR holdings in 10 of the last 12 reported quarters, going back to Q3 2023.
What is Ikarian Capital, LLC's current position in PRQR?
As of Q2 2026, Ikarian Capital, LLC holds 3.43M shares of PRQR (PROQR THRAPEUTICS N V), valued at $6.37M, representing 1.02% of its reported portfolio and ranking #30.
Has Ikarian Capital, LLC been buying or selling PRQR?
In the latest 13F filing (Q2 2026), Ikarian Capital, LLC increased its position in PRQR. The position peaked in Q2 2026 at 3.43M shares.
Which other funds hold PRQR?
Other major institutional holders of PRQR include Privium Fund Management B.V., HEIGHTS CAPITAL MANAGEMENT, INC, Kynam Capital Management, LP, among 35 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.